Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The conversation discusses the use of Minoxidil and finasteride for hair loss and explores the potential of Geranium sibiricum extract as a safer alternative. It highlights the difficulty in finding this specific extract and suggests considering other plants with similar compounds, like Indian gooseberry.

The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.

The user experienced rapid hair growth using Minoxidil, Finasteride, and microneedling, with some initial skin irritation from a retinal serum. They stopped microneedling due to limited results but may continue due to positive anecdotal evidence.

A 23-year-old started using 0.5mg Dutasteride and 2.5mg Minoxidil daily for hair loss and is considering adding RU58841 or GHK-cu. Users suggest waiting a few months before adding anything and mention Koshine's kx-826 as a potentially better alternative to RU58841.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

A 24-year-old has been using finasteride, oral minoxidil, and microneedling for hair loss. They reduced minoxidil due to heartburn and are considering a hair transplant.

Broccoli or sulforaphane supplements are unlikely to improve Minoxidil results due to the need for an unrealistically large dose. Tretinoin, micro-needling, and low-dose oral Minoxidil may be more effective for those lacking the necessary enzyme in the scalp.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

A 40-year-old male using microneedling, low-level laser therapy (LLT), and rosemary oil for hair regrowth. No finasteride or minoxidil is used.

A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.